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Neuroblastoma is a peripheral neural system tumor that originates
from the neural crest and is the most common and deadly tumor of
infancy. Here we show that neuroblastoma harbors frequent
mutations of genes controlling the Rac/Rho signaling cascade
important for proper migration and differentiation of neural crest
cells during neuritogenesis. RhoA is activated in tumors from
neuroblastoma patients, and elevated expression of Rho-associated
kinase (ROCK)2 is associated with poor patient survival. Pharmaco-
logical or genetic inhibition of ROCK1 and 2, key molecules in Rho
signaling, resulted in neuroblastoma cell differentiation and
inhibition of neuroblastoma cell growth, migration, and inva-
sion. Molecularly, ROCK inhibition induced glycogen synthase
kinase 3β-dependent phosphorylation and degradation of MYCN pro-
tein. Small-molecule inhibition of ROCK suppressed MYCN-driven
neuroblastoma growth in TH-MYCN homozygous transgenic mice
and MYCN gene-amplified neuroblastoma xenograft growth in nude
mice. Interference with Rho/Rac signaling might offer therapeutic
perspectives for high-risk neuroblastoma.
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Wnt signaling
Neuroblastoma is a childhood tumor of the peripheral sym-pathetic nervous system, causing 6% of all childhood can-
cers but 9% of deaths from malignant tumors in children (1, 2).
Approximately half of patients present with high-risk disease
characterized by unresectable primary lesions and multiple me-
tastases (2, 3). Although survival in this group has improved, the
majority of the tumors show resistance to therapy with poor
patient survival despite intensive multimodal therapy, necessi-
tating the search for new therapeutic options (2).
Compared with adult tumors, pediatric cancers exhibit signif-
icantly fewer genomic aberrations and mutations. In neuroblas-
toma, somatically acquired amplification of MYCN, hemizygous
deletions of 1p and 11q, and gain of 17q are the most common
chromosomal aberrations associated with a poor prognosis (3).
Exome- and whole-genome sequencing analysis of neuroblas-
toma has reported an overall low somatic mutation count (12 to
18, median 15), with ALK being the most frequently mutated
gene (7 to 10%) (4–6). In addition, chromothripsis, PHOX2B,
and ATRXmutations have also been detected in a subset of high-
risk tumors (4, 5).
Neuritogenesis is initiated during embryogenesis by a transient
population of cells called the neural crest. During embryonic
development, neural crest cells migrate throughout the embryo
and eventually differentiate into multiple cell types, such as
neurons and glial cells of the peripheral nervous system, pigment
cells, fibroblasts, smooth muscle cells, and odontoblasts. The
failure of neural crest cells to differentiate can result in devel-
opment of cancers such as neuroblastoma and melanoma (7). A
combination of Wingless (Wnt), bone morphogenetic protein,
and fibroblast growth factor (FGF) signals is required to induce
the formation of the neural crest and to initiate migration of
neural crest cells by acquiring cell motility through epithelial–
mesenchymal transition (8). The noncanonical Wnt-planar cell
polarity (PCP) signaling cascade is fundamental for the migra-
tion of neural crest cells by controlling contact inhibition of lo-
comotion between neural crest cells. PCP proteins control the
activity of Rho GTPases locally by activating or inhibiting RhoA
and Rac1, resulting in cells migrating away from each other upon
collision (7). The stimulation of Rho signaling by PCP results in
downstream activation of the serine/threonine Rho-associated
coiled coil-containing protein kinases (ROCK)1 and ROCK2
(9). ROCK1 and ROCK2 phosphorylate downstream substrates
such as myosin light chain and LIM kinases 1/2, which further
regulate a range of cellular functions primarily through rear-
rangement of the actin cytoskeleton (10, 11). ROCK is dysre-
gulated in a variety of cancers, including prostate, breast, and
lung cancers, with ROCK overexpression contributing to me-
tastasis by enhancing tumor cell invasion and motility (11).
Here we report that ROCK is a promising target for the
treatment of high-risk neuroblastoma patients expressing high
MYCN levels. We show that genes controlling the activity of
ROCKs are frequently mutated and that high ROCK2 expression
in neuroblastoma tumors corresponds to poor patient survival.
Silencing or pharmacologic inhibition of ROCK induces glycogen
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synthase kinase (GSK)3β-mediated degradation of MYCN, neu-
roblastoma cell differentiation, and suppression of neuroblastoma
growth in preclinical in vivo models.
Results
Neurogenesis Genes Are Frequently Mutated in Neuroblastoma.
Whole-exome and whole-genome sequencing were performed
on human neuroblastoma tumors deriving from different clinical
subsets together with matched germline DNA (n = 40) (Table 1)
or without (n = 25) (SI Appendix, Table S1). Thirteen of the
40 neuroblastoma samples with germline control had at least one
somatic mutation (32.5%) (Table 1), and 18 of the 25 neuro-
blastoma samples profiled contained one or more rare [<0.001%
occurrence in the 1000 Genomes Project; not present in the
Single Nucleotide Polymorphism database (dbSNP) or our in-
house database] genetic protein-changing variants (72%) in the
177 selected genes controlling neuritogenesis (SI Appendix, Ta-
ble S1). The average number of protein-changing mutations in
tumors with germline controls was 19 (2 to 77), whereas 195
(range 44 to 496) protein-changing rare variants were detected in
tumors without matched controls per tumor. Likewise, analysis
of published and validated genomic data from 383 human neu-
roblastoma samples showed at least one somatic protein-
changing alteration in a gene involved in neuritogenesis in
30.5% (117/383) of the samples (SI Appendix, Tables S2 and S3).
For all Rho/Rac-associated genes included in the analysis, see SI
Appendix, Table S4. The most commonly altered gene associated
with neuritogenesis was alpha thalassemia/mental retardation
gene X-linked (ATRX). However, 27.5% of the patients in our
cohort contained at least one mutation or genetic aberration in
genes associated with Rho/Rac signaling (11/40) other than
ATRX (Table 1). The corresponding numbers in the published
cohorts were 25% (97/383) (SI Appendix, Table S3).
In our neuroblastoma cohort, 69% (27/39) were defined as
high-risk disease (defined according to classification systems)
(12, 13). Among the high-risk patients, 37% (10/27) had mu-
tations in Rho/Rac-associated genes, whereas patients with
Rho/Rac gene mutations were found in 25% (3/12) of patients
with intermediate- and low-risk neuroblastoma (Table 1). In
the patient group with mutations in genes in the Rho/Rac
pathway, 9 out of 13 also had 11q deletion, a highly aggres-
sive subgroup of neuroblastoma (Fisher’s exact test, P =
0.038) (Table 1).
ROCKs Are Expressed in Neuroblastoma and ROCK2 Is Associated with
Poor Survival. To investigate the importance of Rho signaling in
neuroblastoma, we analyzed expression levels of the downstream
Rho-activating kinases ROCK1 and ROCK2 in five different
publicly available and validated cohorts of neuroblastoma. For
ROCK1, three datasets showed a significant correlation between
high expression and poor patient overall survival, one dataset
displayed nonsignificant results (but with the same trend), and
one dataset showed the opposite, namely that low expression of
ROCK1 was significantly associated with poor overall survival.
For ROCK2, four datasets showed a significant association be-
tween high expression and poor overall survival, whereas one
dataset presented a nonsignificant result but with the same trend
(SI Appendix, Fig. S1). In conclusion, ROCK2 was detected in
neuroblastoma tumors with higher expression levels being asso-
ciated with poor patient survival (SI Appendix, Fig. S1).
Next, we investigated the protein expression pattern of
ROCK2 and an activated phosphorylated form of ROCK2
(p-Thr396) by immunohistochemistry in neuroblastoma specimens
representing different clinical subgroups. This showed abundant
protein levels of ROCK2 in both the cytoplasm and nucleus in
neuroblastoma tumors (Fig. 1A). Immunohistochemical staining
of the neural marker synaptophysin and phosphorylated
ROCK2 confirmed the localization and expression of ROCK2 in
neuroblastoma cells (SI Appendix, Fig. S2). The most intense
positive staining for phosphorylated ROCK2 (p-Thr396) was
detected in a patient with a non–MYCN-amplified tumor with a
rare variant in the Rho GTPase ARHGEF38 gene (c.C1705T;
p.Q569*, nonsense mutation) and in tumor cells derived from a
patient with MYCN amplification (Fig. 1A). Only moderate
levels of phosphorylated ROCK2 were detected in the low-risk
neuroblastoma patient and in the ganglioneuroma patient sam-
ples (Fig. 1A). In line with these data, measurement of active
RhoA/total RhoA in each investigated patient tumor showed a
higher portion of active RhoA compared with total RhoA in the
neuroblastoma samples exhibiting high ROCK2 phosphorylation
(33% in patient 1 with MYCN amplification and 24% in patient
3 with Rho GTPase ARHGEF38 gene mutation) compared with
tumors showing low ROCK phosphorylation (4.1% in patient
2 with non–high-risk neuroblastoma and 10% in patient 4 with
ganglioneuroma) (Fig. 1B). Also, the relative level of active
RhoA was higher compared with active Rac1 in the neuroblas-
toma sample containing ARHGEF38 mutation (patient 3, SI
Appendix, Fig. S3). Similarly, real-time PCR and Western blot for
ROCK1/2 in a panel of neuroblastoma cell lines, all derived
from high-risk neuroblastoma patients, showed evident levels of
mRNA and protein from both genes (Fig. 1 C and D).
Inhibition of ROCK2 Suppresses Neuroblastoma Growth in Vitro.
Given that ROCK proteins are expressed and activated in sub-
sets of neuroblastoma, we investigated the effect of inhibiting
ROCK activity in neuroblastoma cells. The cytotoxic effects of
the two ROCK inhibitors Y27632 and HA1077 as well as a Rho
inhibitor, Rhosin, were evaluated in a panel of eight human
neuroblastoma cell lines with [IMR32, Kelly, SK-N-BE(2), and
SK-N-DZ] or without MYCN amplification (SK-N-AS, SK-N-FI,
SK-N-SH, and SH-SY5Y). HA1077, an inhibitor of both
ROCK1 and 2 but with a described higher preference for
ROCK2 (14), demonstrated the most effective suppression of cell
growth of the three inhibitors tested (Fig. 2A) and was therefore
selected for continued study. HA1077 showed a concentration-
dependent decrease in cell viability after 72 h of treatment, with
IC50 values ranging between 24.2 and 107 μM (Fig. 2B). The
nontumorigenic fibroblast cell line, MRC5, exhibited a significantly
higher IC50 of 245 μM compared with all investigated neuroblas-
toma cell lines. HA1077 also inhibited the tumorigenic capacity of
SK-N-BE(2), SK-N-AS, and SH-SY5Y cells in a concentration-
dependent manner (Fig. 2C) and suppressed protein expression
of the downstream phosphorylated MYPT1 (Thr696) (Fig. 2D and
SI Appendix, Fig. S4). Similarly, siRNA-mediated down-regulation
of ROCK2 expression significantly suppressed the cell viability of
neuroblastoma cells (Fig. 2E). The knockdown of ROCK2 was
confirmed both on the mRNA and protein level (Fig. 2 F and G).
To minimize the risk for possible off-target effects, we repeated the
experiments using a second siRNA targeting ROCK2. Similar re-
sults on cell viability were obtained for knockdown of ROCK2 in
SK-N-BE(2) cells (SI Appendix, Fig. S5).
ROCK2 Inhibition Induces Differentiation and Decreases Invasion in
Neuroblastoma. Rho kinases are important for proper cell mi-
gration and neural outgrowth (10). We therefore evaluated the
effect of ROCK inhibition on neuroblastoma differentiation,
migration, and invasion. HA1077 treatment reduced the level of
the cell cycle-promoting cyclin D1 protein in the MYCN-ampli-
fied SK-N-BE(2) cell line as well as the non–MYCN-amplified
SH-SY5Y cell line (Fig. 3A and SI Appendix, Fig. S6). Neurite
outgrowth was evident after continuous incubation for 72 h with
sublethal but antiproliferative concentrations of HA1077 in both
SK-N-BE(2) and SH-SY5Y cells (Fig. 3B and SI Appendix, Fig.
S7). The number of cells with neurite outgrowth (neurites >60 μm)
was significantly higher in HA1077-treated cells compared
with untreated (Fig. 3C). Up-regulation of the differentiation
marker β3-tubulin was confirmed in HA1077-treated SK-N-BE(2)
cells (Fig. 3D). Similarly, siRNA-mediated down-regulation of
ROCK2 increased the protein expression of TrkA, another
marker for neural differentiation (Fig. 3D). To investigate the
effects of HA1077 on migration and invasion, we performed ex-
periments in electronically integrated Boyden chambers as
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well as a wound-healing assay. HA1077 was able to reduce the
invasion ability of SK-N-BE(2) toward serum, compared with
untreated control in plates with electronically integrated Boyden
chambers (Fig. 3E). In addition, HA1077 inhibited the rate of
neuroblastoma cell migration in confluent cell monolayers, de-
termined by the wound-healing assay (Fig. 3F). Similar results
were obtained for ROCK2 siRNA-transfected SK-N-BE(2) cells
(Fig. 3F).
Table 1. Somatic mutations in Rho/Rac-associated genes in 40 human neuroblastoma tumors deriving from different clinical subsets
Mutations in Rho/Rac-associated genes Clinical patient characteristics
















1 TENM1 p.I2152L c.6454A>T No Yes Yes No 83 L + DOD 11q del Exome
ATRX Focal del exon 1–15
2 ARHGEF37 p.V70I c.208G>A Yes Yes Yes No 9 L − NED 11q del Exome
3 VAV3 p.R330C c.988C>T No Yes Yes No 21 M + DOD 11q del WGS
4 CSMD1 p.E1766K c.5296G>A Yes No No Yes 41 L + DOD MNA Exome
5 CSMD3 — Tandem insert
exon 28–59
No No No No 38 M + DOD OS Exome/WGS
6 ATRX — Focal del
exon 3–8
No Yes Yes No 28 M + DOD 11q del Exome
7 ATRX — Focal del
exon 8–18
Yes Yes Yes No 55 M + NED 11q del WGS
8 TRIOBP p.I1691T c.2072T>C No Rearr Yes No 22 L − AWD 17q gain WGS
ATRX — Focal del exon 2–9
TENM1 p.E1712K c.5134G>A
9 PTPRD — Focal gain exon 1 Yes No Yes No 66 M + NED/AWD 17q gain WGS
10 ARHGEF7 — t(13, 20)(q34;p12.2) No Yes Yes No 61 M + AWD 11q del WGS
11 TIAM1 p.G719fs*5 c.2156delG Yes Yes‡ No Yes 41 M + DOD MNA/11q del WGS
TIAM1 p.E411Q c.1231G>C
12 ATRX — Focal del exon 2–9 Yes Yes Yes No 50 M + PD 11q del WGS
FZD5 p.Q472K c.1414C>A
13 TENM2 — Tandem insert
exon 1–2
No Yes Yes No 158 M + NED/AWD 11q del WGS
14 No No Yes No 1 M − NED/AWD 17q gain WGS
15 Yes No Yes Yes 21 M + AWD MNA WGS
16 Yes Wcl11 Yes No 83 M + AWD 17q gain WGS
17 Yes Yes Yes No 36 M + AWD 11q del WGS
18 No No Yes Yes 30 M + DOD MNA Exome
19 Yes Inter del Wcg17 Yes 50 M + DOD MNA Exome
20 No Yes Yes No >18 M + NED 11q del Exome
21 No Yes No No 29 M + DOD 11q del Exome
22 Yes Yes Yes No 35 L − DOD 11q del Exome
23 Yes No Yes Yes 20 M + NED/AWD MNA Exome
24 Yes No Yes Yes 37 M + DOD MNA Exome
25 No No Wcg17 No 25 L − NED NO Exome
26 No No Wcg17 No 1 L − NED NO Exome
27 Yes No Yes Yes 13 L + NED MNA Exome
28 No No No No 17 L − NED NO Exome
29 No No Yes Yes N/A N/A + NED/AWD MNA Exome
30 Yes No Yes Yes N/A N/A + DOD MNA Exome
31 Yes No Yes No N/A N/A N/A DOD OS Exome
32 No Yes Yes No 8 M − AWD 11q del WGS
33 No No Wcg17 No 27 L − NED OS WGS
34 Yes No No No 1 M − DOD OS WGS
35 Yes Inter del Yes Yes 11 M + DOD MNA WGS
36 No No Wcg17 Yes 27 M + NED MNA WGS
37 No Yes Yes No 19 M + NED 11q del WGS
38 Yes Yes Yes No 6 M − AWD 11q del WGS
39 Yes No Yes Yes 43 L + DOD MNA Exome/WGS
40 Yes Yes Yes No 29 M + NED 11q del WGS
AWD, alive with disease; del, deletion; DOD, dead of disease; insert, insertion; Inter, interstitial; L, localized; M, metastatic; MNA, MYCN amplification; N/A,
not available; NED, no evidence of disease; NO, numerical only; OS, other structural; Pcl, parts of chromosome loss; PD, progressive disease; Rearr, rearrange-
ment; Wcg, whole-chromosome gain; Wcl, whole-chromosome loss; WGS, whole-genome sequencing.
*INRGSS (International Neuroblastoma Risk Group staging system) stage, modified after Monclair et al. (13); “localized” includes stage L1/L2 [International
Neuroblastoma Staging System (INSS) 1, 2, and 3] and metastatic stage M (INSS 4), except for stage MS (INSS 4S).
†Risk INRG, according to Cohn et al. (12); +, high risk; −, very low risk, low risk, and intermediate risk.
‡Patient presented with additional loss on chromosome 11p.

















ROCK2 Inhibition Suppresses Neuroblastoma Growth in Vivo. To in-
vestigate the therapeutic effects of ROCK inhibition on neuro-
blastoma growth, NMRI nu/nu mice carrying s.c. established SK-
N-BE(2) tumors were treated with 50 mg/kg HA1077 or vehicle
by daily intraperitoneal injection for 10 d. Tumor growth was
significantly inhibited, as the tumor volume was reduced to 69%
compared with vehicle-treated tumors (Fig. 4A). Tumor growth
was also significantly delayed in HA1077-treated animals, mea-
sured as the time until the tumor reached a sixfold tumor volume
(Fig. 4B). As measured by Ki-67 staining, cell proliferation was
significantly inhibited after HA1077 treatment compared with
untreated tumors (Fig. 4C).
Next, we evaluated the therapeutic response of HA1077 in the
genetically engineered mouse model of MYCN-overexpressing
neuroblastoma (TH-MYCN), which recapitulates human high-
risk neuroblastoma (15, 16). Mice homozygous for the MYCN
transgene (TH-MYCN+/+) were treated daily for 9 d by in-
traperitoneal injection of 10 or 25 mg/kg HA1077 starting at the
age of 4.5 wk. Tumor growth was significantly suppressed in
HA1077-treated mice compared with matched control mice; the
mean tumor burden was significantly lower in treated animals
(0.38 g) compared with nontreated animals (1.28 g) (Fig. 4D).
No statistically significant difference in tumor growth inhibition
was detected between the two doses of HA1077 tested (SI Ap-
pendix, Fig. S8). All mice gained in weight during the experi-
ments, and no signs of toxicity were observed in the in vivo
experiments (SI Appendix, Fig. S9). As measured by ELISA,
ROCK activity was lower in the treated tumors compared with
nontreated tumors (Fig. 4E).
Inhibition of ROCK2 Promotes MYCN Protein Degradation. Analysis
of MYCN expression in HA1077-treated mice carrying SK-N-BE(2)
xenografts or tumors developed in TH-MYCN mice showed a
strong reduction of MYCN protein levels compared with non-
treated tumors (Fig. 5 A–C). Similarly, SK-N-BE(2) cells treated
with HA1077 or transfected with ROCK2 siRNA also showed





























































































































































Fig. 1. ROCK2 is expressed in human neuroblastoma tumor samples and cell lines. (A) ROCK2 and phosphorylated ROCK2 (p-ROCK2) in tumors from four
neuroblastoma patients with different clinobiological backgrounds: a high-risk (HR) tumor with MYCN amplification (MNA), non-HR tumor (numerical only
genomic profile), non–MYCN-amplified tumor with a nonsense mutation in ARHGEF38, and benign ganglioneuroma tumor are shown. Images were acquired
at 40× magnification except for p-ROCK2, which is at 60×. H/E, hematoxylin/eosin. (B) Quantification of active RhoA protein, expressed as percent of total
RhoA in the matched patient sample, in the same four neuroblastoma patient (Pat) samples, analyzed with ELISA. Means of five determinations with SEM are
displayed. (C) mRNA expression of ROCK1 and ROCK2 in neuroblastoma cell lines, assessed with real-time PCR. Data represent the mean with SD of three
determinations. (D) Western blot analysis showing ROCK1 and ROCK2 protein levels in all tested neuroblastoma cell lines.
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reduced expression of MYCN (Fig. 5 D and E). Also, immuno-
histochemistry staining of organotypic cultures derived from TH-
MYCN tumors treated with HA1077 ex vivo showed reduced
MYCN protein levels compared with nontreated tumors (SI
Appendix, Fig. S10). However, no differences in MYCN mRNA
levels were observed (Fig. 5 F–H), suggesting that ROCK in-
hibition regulates MYCN expression levels through post-
transcriptional mechanisms. The siRNA experiments were
repeated with a second siRNA targeting ROCK2 with similar
results on MYCN protein and mRNA (SI Appendix, Figs. S5 and
S11). Furthermore, the SH-EP MYCN-inducible Tet21N cell
line, which constitutively overexpresses MYCN under the control
of a tetracycline-responsive repressor element, was more sensi-
tive to HA1077 treatment compared with non–MYCN-induced
cells (Fig. 5I).
Treatment of neuroblastoma cells with HA1077 resulted in
decreased GSK3β (Ser9) phosphorylation (Fig. 6A) and in-
creased MYCN (Thr58) phosphorylation (Fig. 6B), whereas
treatment with the small-molecule GSK3β inhibitors CHIR99021 or
SB-216763 in combination with HA1077 resulted in increased
GSK3 (Ser9) phosphorylation and increased MYCN protein
levels (SI Appendix, Fig. S12). Finally, analysis of publicly avail-
able and validated gene signature data revealed significant
correlation between ROCK2 and MYCN expression in neuro-
blastoma. Additionally, ROCK2 expression was significant higher
in MYCN-amplified samples (SI Appendix, Fig. S13).
Discussion
The Rho family of GTPases is fundamental for correct polari-
zation, locomotion, and migration of neural crest cells during
embryonal development. Given the importance of Rac/Rho
signaling during development, it is not surprising that several of
the Rho GTPases are frequently deregulated in cancer (17, 18).
Our data from whole-exome and whole-genome sequencing of
primary neuroblastoma tumors showed frequent occurrence of
mutations within the Rho family of GTPases and associated
genes (Table 1). Recurrent mutations within Rho-family genes
have been reported by others (5, 6), and analysis of our neuro-
blastoma cohort demonstrated that 27.5% of neuroblastoma
tumors contain at least one mutation within Rho/Rac-associated
genes, excluding the ATRX gene (Table 1 and SI Appendix, Table
S3). Intriguingly, we found a significant accumulation of patients
with an 11q deletion in the group with mutations associated with
Rho/Rac signaling in our investigated cohort (Table 1). Others
have shown an association between mutations in Rho/Rac genes
and aggressive high-stage neuroblastomas without MYCN am-
plification, which is in line with our findings (5). However, we
could not confirm the correlation with high-risk disease, possibly
because our investigated cohort mainly consisted of high-risk
patients. Mutations of Rho GTPase genes have been detected
at low frequencies in various tumor types (19). Interestingly,
recurrent somatic oncogenic driver mutations of Rac1 have been
detected in 5 to 9% of tumor DNA from patients with mela-
noma, a tumor that, similar to neuroblastoma, also originates
from cells within the neural crest (20, 21). This suggests that the
mutations of Rho GTPases and associated genes seen in neu-
roblastoma and melanoma are acquired during migration and
differentiation of neural crest cells. The neural crest consists of
multipotent stem cells that during migration give rise to a
plethora of differentiated cells, including cells of the peripheral
nervous system and adrenal medulla and melanocytes. Because
of the versatility and mobility of neural crest cells, they are ex-
posed to both cell-autonomous factors and environmental cues
that may lead to an inappropriate differentiation giving rise to
peripheral nervous system diseases prevalent in pediatric pop-
ulations (22).
Our analyses of publicly available expression arrays show that
high expression of the Rac/Rho downstream signaling molecule
ROCK2 is significantly correlated with high-risk neuroblastoma
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Fig. 2. ROCK inhibition suppresses neuroblastoma
growth. (A) IC50 (μM) for the Rho/Rac signaling in-
hibitors Y27632, HA1077, and Rhosin in a panel of
neuroblastoma cell lines after a 72-h drug exposure.
The ROCK inhibitor HA1077 showed significantly
lower log IC50 than the ROCK inhibitor Y27632 and
the Rho inhibitor Rhosin (repeated-measures one-
way ANOVA, P = 0.0067; Y27632 vs. HA1077, P =
0.001; Rhosin vs. HA1077, P = 0.0457). (B) Dose–re-
sponse curves for cell viability after 72 h of
HA1077 treatment in eight neuroblastoma cell lines
and one fibroblast cell line, MRC5 (used as a non-
tumorigenic control for drug toxicity). Cell viability
was determined with WST-1; IC50 values are dis-
played (Right). The cell lines are labeled identically in
A and B. (C) Tumorigenic capacity, shown as clono-
genic forming ability, was inhibited in the three
tested neuroblastoma cell lines after 96 h of HA1077
exposure. (D) The expression of phosphorylated MYPT1
was decreased in neuroblastoma cells following
treatment with HA1077 (48 h), as shown by Western
blotting. Quantification showed a ratio for p-MYPT1/
total MYPT1 of 0.41 vs. 0.15. (E) siRNA-mediated
down-regulation of ROCK2 (siROCK2) expression
suppressed neuroblastoma cell viability 72 h after trans-
fection compared with scrambled control (scrambl.
control) [t test; SK-N-BE(2), ***P < 0.0001; SK-N-AS,
***P = 0.0003]. (F and G) The siRNA knockdown of
ROCK2 was confirmed with quantitative PCR and
Western blotting [t test; SK-N-BE(2), **P = 0.047; SK-
N-AS, ***P = 0.0004]. All concentrations were tested
in duplicates, and the experiments were repeated at
least three times; mean (A) and mean with SD (B, C,
E, and F) are displayed.

















expression of ROCK1 was not as clear in the investigated data-
sets (SI Appendix, Fig. S1). Possible explanations of the disparity
in ROCK1 and ROCK2 involvement may be differences in tissue
expression and role during embryonic development, and similar
differences have been considered in other malignancies (23, 24).
Our data also indicate that mutations within Rho GTPase sig-
naling may activate RhoA and increase the activity of down-
stream ROCK proteins, as shown by immunohistochemistry
of primary neuroblastoma samples using antibodies detecting
phosphorylated activated ROCK2 (Fig. 1A). Similarly, genome-
and transcriptome-wide analysis of high-risk neuroblastomas
showed correlation between deregulation of Rho GTPase sig-
naling and high-risk neuroblastoma independent of MYCN gene
amplification status (25). We therefore investigated the effects of
inhibiting the activity of ROCK molecules in neuroblastoma
using specific small-molecule inhibitors of ROCK or RNAi-
mediated gene silencing. We show here that the inhibition of
ROCK destabilizes MYCN proteins, induces neuroblastoma cell
differentiation, and suppresses migration and invasion. The
ROCK-specific inhibitor HA1077 also significantly inhibited the
growth of established neuroblastoma xenograft tumors in nude
mice as well as suppressed neuroblastoma growth in the MYCN-
driven TH-MYCN mouse model of neuroblastoma. In preclinical
in vivo models, the levels of MYCN in the tumor tissue were
markedly decreased in HA1077-treated animals (Figs. 4 and 5).
One important mechanism for regulating MYCN expression is
the cell cycle-dependent phosphorylation of MYCN proteins by
the cell-cycle kinase cyclin B/CDK1 and GSK3β that results in
Fbxw7 ubiquitin ligase-mediated proteasomal degradation (26).
Our results demonstrate that inhibition of ROCK results in de-
phosphorylation of GSK3β (Ser9) and induction of MYCN
(Thr58) phosphorylation followed by diminished MYCN protein
levels. GSK3β is fundamental during neural morphogenesis
through the regulation of neural polarization, axon growth, and
axon branching (27). Interestingly, the activity of GSK3β is partly
regulated by molecular cross-talk with ROCK through mutual
protein phosphorylation (28). Hence, the mutations of Rho
GTPases or associated genes that alter Rho/Rac signaling and
enhance the activity of ROCK may affect the levels of MYCN pro-
teins in neuroblastoma because active ROCK can phosphorylate and
inactivate GSK3β, resulting in deregulated MYCN protein levels.
The importance of the different mutations of Rho GTPases and
associated genes in neuroblastoma is not known. The majority of
these mutations have the potential to activate RhoA and inhibit
Rac1 (5), which is supported by RhoA activity assays presented in
this study. However, further studies will be needed to verify whether
these mutations are oncogenic in subsets of neuroblastoma.
Taken together, our data demonstrate that ROCK is a drug-
gable target in neuroblastoma and that ROCK inhibitors may
represent a therapeutic opportunity for neuroblastoma patients
with advanced disease.
Materials and Methods
Cell Culture and Reagents. Apanel of nine humanneuroblastoma cell lines, with
different stage and MYCN genetic characteristics, were grown in DMEM/F12
(SH-SY5Y) or RPMI 1640 [SK-N-BE(2), SK-N-AS, SK-N-FI, SK-N-SH, SK-N-DZ, Kelly,
IMR32, and Tet21N] medium supplemented with 10% FBS (Gibco), 2 mM
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Fig. 3. ROCK2 inhibition induces differentiation and
inhibits proliferation and invasion in neuroblastoma
cell lines. (A) Treatment of SK-N-BE(2) and SH-SY5Y
neuroblastoma cells with HA1077 reduced the ex-
pression of cyclin D1 protein as shown by Western
blotting. Quantification with densitometry demon-
strated a ratio between cyclin D1 and loading control
in SK-N-BE(2) of 1 (untreated) compared with 1.06
(25 μM) and 0.26 (50 μM) in HA1077-treated cells;
corresponding quantification in SH-SH5Y showed
1 compared with 0.60 and 0.48. (B) Neural differen-
tiation of SK-N-BE(2) and SH-SY5Y in response to
HA1077 (50 μM, 72 h) and retinoic acid (ATRA; 1 μM,
72 h). Cells were stained with β3-tubulin and Hoechst
33342, and images were acquired using a confocal
laser-scanning microscope (Leica; TCS SP5; 20× ob-
jective). (C) The number of cells with neurite out-
growth (>60 μm) was manually counted (ANOVA
with Bonferroni posttest; SK-N-BE(2), P < 0.0001;
control vs. HA1077, *P = 0.033; control vs. ATRA,
***P = 0.0003; SH-SY5Y, P = 0.0002; control vs.
HA1077, ***P = 0.0002; control vs. ATRA, **P =
0.0065). Means with SD are shown. (D) Up-regulation
of the differentiation markers β3-tubulin in HA1077-
treated cells (72 h) and TrkA after silencing of ROCK2
(96 h) compared with controls. (E) HA1077 (50 μM)
repressed the invasion ability of SK-N-BE(2) cells
when studied in a real-time invasion analysis in cell
chambers coated with 5%Matrigel, monitored in the
xCELLigence real-time cell analysis system (two-way
ANOVA, P = 0.049 for treatment over 30 h; Bonfer-
roni posttest, P < 0.05 from time point 24 h). Means
with SD of three independent experiments are dis-
played. (F) ROCK2 inhibition, by HA1077 or siRNA
knockdown, inhibited neuroblastoma migration,
shown as the relative area of migrated cells 18 h
after scratching measured by wound assay. Means
with SD of three independent experiments are
shown [t test; SK-N-BE(2), *P = 0.031; SH-SY5Y, *P =
0.028; SK-N-BE(2) siRNA, **P = 0.0054].
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Thermo Scientific) in a 37 °C humidified, 5% CO2 atmosphere. Also, a fibroblast
cell line, MRC5 (grown in RPMI 1640 supplemented and grown as described
above), was used. All media were purchased from Gibco. Tet21N is derived
from the neuroblastoma SH-EP cell line and contains a tetracycline-regulated
MYCN transgene. The cells were grown as MYCN ON and MYCN were switched
OFF (+doxycycline) 24 h before experiments.
The identities of the cell lines were verified by short tandem repeat genetic
profiling using the AmpFLSTR Identifiler Direct PCR Amplification Kit (Ap-
plied Biosystems) in January 2014, and all cell lines were used in passages
below 25. All experiments were executed in Opti-MEM (Gibco) supplemented
with glutamine, streptomycin, and penicillin, with the exception of the
transfection experiments, which were performed without antibiotics.
HA1077 dihydrochloride was purchased from LC Laboratories or Sigma-
Aldrich; Y27632 dihydrochloride, all-trans retinoic acid, and doxycycline
from Sigma-Aldrich; Rhosin from Calbiochem (Merck Millipore);
CHIR99021 from Miltenyi; and SB-216763 from Sigma-Aldrich. HA1077 and
Y27632 were dissolved in sterile water or 150 mM NaCl, and Rhosin, retinoic
acid, doxycycline, CHIR99021, and SB-216763 were dissolved in DMSO
(Sigma); further dilutions were done with Opti-MEM or PBS.
For the transfections, cells were seeded in six-well dishes, left to attach, and
transfected using Lipofectamine 2000 with 20 pmol predesigned siRNAs
targeting human ROCK2 (5270301; Invitrogen) and nontargeting siRNA
(6568s; Invitrogen) as control or ROCK2 (locus ID 9475; SR306287) and
scrambled negative control siRNA (OriGene Technologies). After 48 to 96 h,
cells were subjected to further analyses.
Viability Assays. The effects of ROCK inhibitors on cell growthwere determined
using a colometric formazan-based cell-viability assay (WST-1; Roche) according
to the manufacturer’s description. Cells were seeded onto 96-well plates
[10,000 cells per well except SK-N-BE(2), 5,000 cells per well] and incubated
with drugs for 72 h. All concentrations were tested in triplicate.
To determine colony formation, 200 cells were seeded on six-well plates
(Cell+; Sarstedt) in triplicate. Cells were left to attach before treatment with
HA1077 for 96 h or genetic ROCK2 down-regulation. After 8 to 14 d of in-
cubation in drug-free medium, cell cultures were washed, fixed in formal-
dehyde, and stained with Giemsa (Gibco). Colonies (>100 cells) with 50%
plate efficiency were manually counted using a colony counter.
Western Blotting. Protein extraction andWestern blotting were performed as
described earlier (29). Membranes (PVDF; Millipore) were incubated with
antibodies against ROCK1 (1:1,000; 160 kDa), ROCK2 (1:1,000; 160 kDa),
cyclin D1 (1:1,000; 36 kDa), TrkA (1:1,000; 140 kDa), MYCN (1:500; 62 kDa),
β-actin (1:5,000; 45 kDa), GSK3β (1:1,000; 46 kDa), GSK3α/β phospho S21/S9
(1:1,000; 51 and 46 kDa), β3-tubulin (1:1,000; 55 kDa), MYPT1 (1:1,000;
140 kDa), phosphorylated MYPT1 (Thr696) (1:500; 140 kDa) (all from Cell
Signaling), MYC phospho (T58/S62) (1:1,000; 57 to 65 kDa), GAPDH (1:10,000;































































































































Fig. 4. HA1077 reduces neuroblastoma growth in vivo. (A) HA1077 significantly impaired the growth of established human neuroblastoma xenografts in
NMRI nu/nu mice (t test, day 10, *P = 0.038; two-way ANOVA, regarding treatment, P = 0.016). Mice were engrafted with 10 × 106 SK-N-BE(2) cells s.c. and
randomized to receive a daily i.p. injection of HA1077 (50 mg/kg; n = 8) or vehicle (n = 11) for 10 d, starting at the appearance of palpable tumors of
≈0.10 mm3 (mean 0.125 mm3). Means with SEM are displayed. (B) Tumor growth was significantly delayed in HA1077-treated animals, measured as time until
tumor reached sixfold tumor volume (log-rank test, *P = 0.0301). (C) Cell proliferation was inhibited in tumors from mice treated with HA1077 compared with
untreated controls, shown by tumor Ki-67 immunostaining (t test, *P = 0.033). Representative images and quantification, with means with SD, are shown.
(D) Tumor weights from mice homozygous for the MYCN transgene (TH-MYCN+/+) treated with HA1077 [10 mg/kg (▪) or 25 mg/kg (♦); n = 11, mean 0.38 g]
were significantly reduced after 10 d of treatment (starting at 4.5 wk of age) compared with matched control (n = 19; mean 1.28 g) (t test, ***P = 0.0001).
Tumor weights from individual mice are shown, with lines representing the mean. (E) ROCK activity in TH-MYCN HA1077-treated tumors (n = 6) and control
tumors (n = 3), measured by ROCK activity ELISA. Means with SD are presented.

















62 kDa) (Santa Cruz Biotechnology). Anti-rabbit IgG, conjugated with
horseradish peroxidase (Cell Signaling), was used for secondary detection
and SuperSignal (Pierce) was used for chemiluminescent visualization.
Quantification of blots was done with densitometry measurements in
ImageJ (30).
Real-Time RT-PCR. Total RNA was prepared from cells and tumors with the
RNeasy Kit (Qiagen), followed by cDNA synthesis with the High-Capacity RNA-
to-cDNA Kit (Applied Biosystems). The mRNA expression levels of ROCK1,
ROCK2, MYCN, and housekeeping genes were assessed using TaqMan (Ap-
plied Biosystems) technology on an ABI PRISM 7500 Sequence Detection
System (Applied Biosystems). The TaqMan sequence-specific primers were
ROCK1 (Hs01127699_m1), ROCK2 (Hs00178154_m1), MYCN (Hs00232074_m1),
and 18S ribosomal RNA (Hs99999901_s1) (Applied Biosystems). Relative quan-
tification was determined with a standard curve. All real-time RT-PCR experi-









































































































































































































































Fig. 5. Inhibition of ROCK2 promotes degradation of MYCN protein. (A and B) Immunohistochemistry analysis of MYCN expression in HA1077-treated mice
carrying SK-N-BE(2) xenografts (A) or TH-MYCN mice (B) showed reduced levels of MYCN protein levels compared with nontreated tumors. Representative
images (acquired at 20× magnification) are shown, including isotype controls. (C) Western blot analysis of MYCN expression in tumors from HA1077-treated
TH-MYCN mice confirmed suppression of MYCN protein levels compared with tumors from untreated controls. (D) HA1077 exposure (50 μM, 96 h) reduced
MYCN protein expression in SK-N-BE(2) cells. (E) Inhibition of ROCK2mRNA expression by siRNA suppressed MYCN protein levels (72 h). (F) Relative expression
of MYCN mRNA from the same TH-MYCN tumors as in C demonstrated no differences in mRNA levels of MYCN for HA1077-treated tumors compared with
tumors from untreated mice (t test, P = 0.72). (G) No decrease in MYCN mRNA levels was observed in SK-N-BE(2) cells treated with HA1077. On the contrary,
mRNA MYCN levels were increased (one-way ANOVA, P = 0.015; Bonferroni posttest: control vs. HA1077, 25 μM, P = 0.033; control vs. HA1077, 50 μM, P =
0.015). (H) Inhibition of ROCK2 mRNA expression by siRNA (72 h) induced no effect on MYCN mRNA in SK-N-BE(2) neuroblastoma cells (t test, P = 0.30).
Protein levels were studied with Western blot (C–E), and quantification of mRNA was assessed with real-time quantitative PCR (F–H). Data are presented as
means and SD of three determinations (F–H). (I) IC50 (μM) for HA1077 was significantly lower in the SH-EP MYCN-inducible Tet21N cell line with constitutive
overexpression of MYCN, compared with non–MYCN-induced cells (t test, **P = 0.003). Means with 95% confidence intervals are shown from four experi-
ments, determined with WST-1.
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Differentiation and Migration Studies. To study differentiation, a morpho-
logical evaluation of neuroblastoma cells was performed after exposure to
HA1077 or retinoic acid or no treatment (72 h). SK-N-BE(2) and SH-SY5Y cells
were seeded on eight-well chamber slides (Nunc) [5,000 cells per well for SK-
N-BE(2) and 12,500 cells per well for SH-SY5Y], left to attach, and treatedwith
the indicated drug concentrations. After 72 h, neuroblastoma cells were fixed
and immunostained with an antibody against neuron-specific β3-tubulin
(1:800) followed by anti-mouse IgG Alexa Fluor 488 (1:1,000) and with
Hoechst 33342 (20 μM) (Sigma). Images were taken using a confocal laser-
scanning microscope (Leica; TCS SP5) and evaluated for neurite outgrowth.
The number of cells with neurite outgrowth (>60 μm) was manually counted
by researchers blinded to treatment, and more than 300 cells for each
treatment were analyzed in randomized selected images (>5 images). In
addition, neuroblastoma cells were seeded on six-well plates (75,000 cells
per well), left to attach, and treated, and images were acquired with a
phase-contrast microscope (Nikon; Eclipse TS100; 20× objective).
A wound assay was performed to evaluate the migration capacity after
ROCK inhibition in neuroblastoma cells, or by HA1077 treatment or siRNA
against ROCK2. SK-N-BE(2) and SH-SY5Y cells were seeded on six-well plates
(500,000 cells per well) and left to attach for 24 h. A “wound” was made
using a 200-μL pipette tip, followed by drug treatment. Images were taken
at the start (t = 0) and 18 h after treatment (t = 18) using a phase-contrast
microscope (Olympus; Infinity 1; 20× objective), and used for quantitative
assessment of the migrated area (31). Assessment was done using auto-
mated analysis in TScratch software (32). Three independent experiments
were performed with at least three images per treatment.
A cell-invasion assay was performed on 16-well cell migration/invasion
plates with an 8-μm polyethylene terephthalate membrane coated with 5%
Matrigel (growth factor reduced; Corning) in an xCELLigence DP instrument
for real-time analysis (ACEA Biosciences). SK-N-BE(2) cells, after starvation in
serum-free RPMI medium for 6 h, were seeded in the upper chamber in
serum-free medium containing HA1077 (50 μM) or vehicle. The lower
chamber contained complete RPMI medium (10% FCS), and cell invasion was
monitored every 2 h for a period of 30 h. All treatments were performed in
at least triplicate, and experiments were repeated three times.
Human Tissue Samples. Neuroblastoma tissue from patients was obtained
during surgery and stored at −80 °C. Ethical approval was obtained from the
Karolinska University Hospital Research Ethics Committee (approval nos.
2009/1369-31/1 and 03-736). Informed consent for using tumor samples in
scientific research was provided by parents/guardians. In accordance with
the approval from the Ethics Committee the informed consent was either
written or verbal, and when verbal or written assent was not obtained the
decision was documented in the medical record.
Immunohistochemistry. Formalin-fixed and paraffin-embedded (FFPE) tissue
slides were deparaffinized in xylol and rehydrated in graded alcohols. For
antigen retrieval, slides were boiled in a sodium citrate buffer (pH 6.0) for
10 min in a microwave oven. After blocking in 1% bovine serum albumin
(BSA) for 20 min, the tissue sections were incubated with primary antibody
against ROCK2 (H-85; Santa Cruz Biotechnology), ROCK2 (p-Thr396; Novus
Biochemicals), or N-Myc (B8.4.B; Santa Cruz Biotechnology) diluted 1:150 in 1%
PBS with 1% BSA overnight at 4 °C. Thereafter, slides were rinsed in PBS and
endogenous peroxidases were blocked in 0.3% H2O2 for 10 min. As a sec-
ondary antibody, anti-rabbit horseradish peroxidase was used (Invitrogen).
All slides were counterstained with hematoxylin. Matched isotype control
was used as a control for nonspecific staining. The presence of activated
ROCK2 in neuroblastoma cells was assessed by double immunofluorescence
labeling of tissue slides using a mouse monoclonal anti-synaptophysin anti-
body (clone SVP-38; Sigma) and rabbit anti-ROCK2 (p-Thr396; Novus Bio-
chemicals). For fluorescence visualization, donkey anti-mouse Alexa
594 and goat anti-rabbit Alexa 488 were used, respectively.
FFPE sections from SK-N-BE(2) xenografts were deparaffinized and rehy-
drated before endogenous peroxidase activity was blocked using 0.5% H2O2,
and biotin was blocked using 1% BSA in Tris-buffered saline for 30 min.
Tumor sections were incubated overnight at 4 °C with primary antibody
against Ki-67 (1:200; Thermo Scientific). Sections were then incubated for
40 min at RT (room temperature) with a biotin-conjugated secondary anti-
body (anti-rabbit; 1:200; Vector Laboratories). After incubation with ABC
complex (Vector Laboratories), the sections were developed for 6 min
using diaminobenzidine (DAB Peroxidase Substrate Kit; Vector Laborato-
ries) and then counterstained with Mayer hematoxylin (Histolab). Quantifi-
cations were done at 20× magnification. Sixty randomly chosen fields per
slide and five slides per group were automatically quantified using Leica
Qwin IM500 software, and are presented as the proportion of positive
staining of the total area.
Sequencing Analyses. DNA was extracted from frozen tumors using standard
procedures and evaluated through fluorometric quantitation and DNA in-
tegrity assessment on an Agilent TapeStation prior to exome or whole-
genome sequencing. Exome sequencing was performed through pair-end
sequencing on Illumina platforms after enrichment with an Agilent Sure-
Select All Exome Enrichment Kit. Alignment against hg19 was performed
using BWA (bio-bwa.sourceforge.net) with GATK local realignment followed
by single-nucleotide variance calling using SNPeff (www.sourceforge.net).
Whole-genome sequencing was performed on tumor DNA and corre-
sponding constitutional DNA extracted from blood for 13 neuroblastoma
patients for an average coverage of at least 60× for tumor and 30× for
constitutional DNA using Illumina X Ten instrumentation located at National
Genomics Infrastructure/Clinical Genomics, SciLife Laboratories. Read trim-
ming, mapping to the human reference genome hg19, and variant calling
were performed using CLC Genomics Workbench 8.0.3 software (https://
www.qiagenbioinformatics.com/).
Only high-quality called variants with a minimum 10% allele frequency
and a total read coverage of 10 were considered for further analysis. Variants
with allele frequency above 3% in either 1000 Genomes Project (www.
internationalgenome.org), Exome Aggregation Consortium (ExAC) (exac.
broadinstitute.org), or National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project (evs.gs.washington.edu/EVS/) were discarded as
well as excluding all synonymous variants or variants in noncoding regions
except those affecting canonical splice sites. Remaining variants were
assessed manually through the Integrative Genomics Viewer (33) for re-
moval of calls due to mapping artifacts and paralogs.
For tumors (exome) sequenced without corresponding DNA from consti-
tutional tissue, a systematic filtering approach was used to identify critical
variants. This was done by removal of common variants, for example, present
in dbSNP version 138 or showing an allele frequency above 0.1 in either 1000
Genomes Project, ExAC, or NHLBI Exome Sequencing Project. A set of
177 genes with known function in the Rho-Rac signaling cascade, including
Rho-Rac–controlling GEFs and GAPs, and other signaling molecules in the
noncanonical Wnt signaling pathway was preselected for mutational anal-
ysis. Detected somatic protein-changing aberrations in these genes were
compiled with all previously reported mutations in human neuroblastoma
samples available in recent publications (5, 6, 34) (SI Appendix, Tables S2 and
S3). Kaplan–Meier survival curves and gene correlations were produced with
the R2 Genomics Analysis and Visualization Platform (r2.amc.nl).
RhoA, Rac1, and ROCK Activity Assays. Total RhoA, active RhoA, and active
Rac1 were investigated using ELISA and G-LISA kits (BK150, BK124, and
BK128; Cytoskeleton). The RhoA G-LISA kit uses a plate coated with Rho-GTP–
binding protein, and thus active, GTP-bound Rho in lysates will bind whereas
inactive GDP-bound Rho will be washed away, and the Rac1 G-LISA plate will
correspondingly bind active, GTP-bound Rac1. ROCK kinase activity was
analyzed by an enzyme immunoassay measuring the phosphorylation of
myosin phosphatase target subunit 1 (MYPT1) at Thr696 (STA-416; Cell
Biolabs). The experiments were performed according to the manufacturer’s
protocol. The total protein quantity for samples for detecting total RhoA
was 30 μg, for active RhoA and active Rac1 was 50 μg, and for ROCK was 750 μg
protein.
In Vivo Studies. For the xenograft study, SK-N-BE(2) cells (10 × 106) were
















































Fig. 6. ROCK inhibition induces GSK3β-mediated phosphorylation and
degradation of MYCN protein. HA1077 decreased the protein expression of
phosphorylated GSK3α/β (Ser21/9) (A) and increased phosphorylated MYCN
(T58) (B) in neuroblastoma cells, determined with Western blotting (72 h).

















5- to 6-wk-old Sca:NMRI-nu/nu, Scanbur). At palpable tumor, with a
volume greater than 0.10 mm3, the mice were randomized to receive
either HA1077 intraperitoneally (50 mg/kg, n = 7) or vehicle (n = 11) for
10 d. Tumors were measured daily, and tumor volume was calculated as
width2 × length × 0.44. Tumor volume index was calculated as the measured
tumor volume each day divided by the starting volume (day 0). The
TH-MYCN animals were obtained from the Mouse Models of Human Cancers
Consortium Repository as an N16 backcross to the 129X1/SvJ background
and were kept as a continuous inbreeding. Genotyping, abdominal palpa-
tions, and tumor development were previously described (15). In the treat-
ment study, homozygous mice were randomized at 4.5 wk of age to receive
either no treatment (control; n = 19) or daily intraperitoneal injections with
HA1077 (10 mg/kg, n = 6 or 25 mg/kg, n = 5) for 10 consecutive days, and
were killed at the age of 6 wk. Some animals in the control group have been
used in other published studies. Animals were maintained at a maximum of
six per cage and given sterile water and food ad libitum. The animals were
monitored for signs of toxicity, including weight loss. At sacrifice, tumors
were dissected into smaller parts and either frozen or fixed in formaldehyde
for further analysis. All animal experiments were approved by the regional
ethics committee for animal research (N391/11 and N26/11), appointed and
under the control of the Swedish Board of Agriculture and the Swedish
Court. The animal experiments presented herein were in accordance with
national regulations (SFS 1988:534, SFS 1988:539, and SFS 1988:541).
Organotypic Cultures. Neuroblastoma tumors from TH-MYCN mice were used
to create organotypic slice cultures (35). The tumor was sliced into 300-μm-
thick transversal slices using a McIlwain tissue chopper (Ted Pella). The slices
were moved to culture medium DMEM:F12K 1:1 supplemented with 2 mM
L-glutamine, 1% penicillin-streptomycin, EGF (10 ng/mL medium; Chemicon),
FGF (15 ng/mL medium; ProSpec), and B27 (1:50; Sigma) and then carefully
placed on insert membranes (Millicell culture plate inserts; Millipore) on six-
well plates. The membranes were coated with 0.3 mL of 0.1 mg/mL poly-D- or
poly-L-lysine in advance. One milliliter of culture medium was put un-
derneath the membrane and all fluid on top was removed. The cultures
were kept in an incubator (37 °C, 5% CO2) and the culture medium was
changed every second day. Control cultures always received regular culture
medium, and treated slices received culture medium with 50 μM HA1077.
After 7 d, slices were fixed in 4% paraformaldehyde for 1 h at 4 °C and then
in 20% ice-cold methanol in PBS for 10 min. Triton X-100 (0.2%; Roche Di-
agnostics) and 0.1% Tween 20 (Invitrogen) in PBS was used for per-
meabilization for 40 min at RT, and 5% BSA (Invitrogen) with 0.05% Tween
20 in PBS was used for blocking for 2 h at RT with primary antibodies against
ROCK2 (H-85) and N-MYC (B8.4.B) (Santa Cruz Biotechnology) and then di-
luted 1:200 in 0.05% Tween 20/PBS and incubated at 4 °C for 48 h. After a
washing, slices were incubated for 1.5 h at RT with secondary antibodies
(Alexa; Invitrogen) diluted 1:200 in 0.05% Tween 20/PBS. After a second
washing in PBS, the slices were mounted in ProLong Gold Antifade Reagent
with DAPI (Invitrogen; P36931). Stainings were analyzed with a Zeiss Axio
Examiner D1 microscope (10×, 20×, and 40× water-immersion objectives)
with a cooled CCD camera (Zeiss), and captured images were processed in
ImageJ (1.42q; National Institutes of Health).
Statistics. IC50 values (inhibitory concentration 50%) were determined from
log concentration–effect curves in Prism (GraphPad Software) using non-
linear regression analysis. Fisher’s test was used to examine the significance
of the association between the two categories. Comparison between two
groups was done with the Student t test and, for comparison of three or
more groups, one-way ANOVA followed by Bonferroni multiple compari-
sons posttest was used. Treatment groups with repeated measurements
over time were compared with two-way ANOVA followed by Bonferroni
multiple comparisons posttest. All tests were two-sided and carried out
in Prism.
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